Interim results from the ongoing clinical studies I/II phase COV001, which is held by Oxford University, showed the tolerability of the vaccine AZD1222, and the development of enhanced immune response against the virus SARS-CoV-2 all participants in the study.
COV001 is blind multicenter randomized controlled trial I/II phase involving 1077 healthy volunteers aged 18 to 55 years. The study evaluated a single immunization AZD1222 compared with meningococcal conjugate vaccine MenACWY. Ten of the study participants received two doses AZD1222 with an interval of one month.
The results, published in the Lancet, confirmed that a single administration AZD1222 results in a fourfold increase of antibodies to thorn the squirrel virus SARS-CoV-2 95% of participants a month after vaccination. All participants noted the activation of T-cell immune response, which reached a peak by day 14 and persisted for 2 months after injection.
The neutralizing activity of the antibodies against the virus SARS-CoV-2 (a rating which was carried out using the analyzer MNA80) was identified in 91% of the participants one month after vaccination and those who received re-injection. The levels of neutralizing antibodies observed in participants who received one or two doses were comparable with the data of recovering patients with coronavirus infection. A strong correlation was observed in the analysis of neutralization.
Research late phase II/phase III are currently underway in the UK, Brazil and South Africa, and will start soon in the United States. They will determine how well the vaccine can protect against COVID-19 and to assess its safety and immunogenicity for persons of different ages and in different doses.